Production of recombinant human interleukin-38 and its inhibitory effect on the expression of proinflammatory cytokines in THP-1 cells
- Authors: Yuan X.L.1, Li Y.1, Pan X.H.1, Zhou M.1, Gao Q.Y.1, Li M.C.1
-
Affiliations:
- Zhejiang Provincial Key Laboratory of Pathophysiology, Department of Immunology
- Issue: Vol 50, No 3 (2016)
- Pages: 405-411
- Section: Molecular Cell Biology
- URL: https://journal-vniispk.ru/0026-8933/article/view/162670
- DOI: https://doi.org/10.1134/S0026893316030134
- ID: 162670
Cite item
Abstract
Interleukin (IL)-38 is the latest member of the IL-1 cytokine family. However, as a result of lacking efficient method to generate relatively large quantity of IL-38, its precise functions are poorly understood. In the present study, the cloning, expression, purification, and activity analysis of recombinant human IL-38 was described. Human IL-38 cDNA was cloned into the prokaryotic expression vector pET-44. The recombinant IL-38 containing a C-hexahistidine tag was expressed in Escherichia coli BL21 (DE3) which induced by isopropyl-β-D-thiogalactoside. The expressed fusion protein was purified by Ni-NTA affinity chromatography. IL-38 protein was largely found in the soluble fraction. The purified IL-38 appeared a single band on SDS-PAGE, the yield of IL-38 was 4 mg from 1 L of bacterial culture, and the purity was more than 98% with low endotoxin level (<0.1 EU/μg). Western blotting confirmed the identity of the purified protein. Activity analysis showed that IL-38 can inhibit effectively the expression of proinflammatory cytokines, such as tumor necrosis factor-α, IL-1β, IL-17, and monocyte chemoattractant protein-1 in lipopolysaccharide-activated THP-1 cells. The production and characterization of biologically active IL-38 will be beneficial for its potential role in clinical applications.
About the authors
X. L. Yuan
Zhejiang Provincial Key Laboratory of Pathophysiology, Department of Immunology
Email: limingcai@nbu.edu.cn
China, Ningbo, 315211
Y. Li
Zhejiang Provincial Key Laboratory of Pathophysiology, Department of Immunology
Author for correspondence.
Email: yanli319@yahoo.com
China, Ningbo, 315211
X. H. Pan
Zhejiang Provincial Key Laboratory of Pathophysiology, Department of Immunology
Email: limingcai@nbu.edu.cn
China, Ningbo, 315211
M. Zhou
Zhejiang Provincial Key Laboratory of Pathophysiology, Department of Immunology
Email: limingcai@nbu.edu.cn
China, Ningbo, 315211
Q. Y. Gao
Zhejiang Provincial Key Laboratory of Pathophysiology, Department of Immunology
Email: limingcai@nbu.edu.cn
China, Ningbo, 315211
M. C. Li
Zhejiang Provincial Key Laboratory of Pathophysiology, Department of Immunology
Author for correspondence.
Email: limingcai@nbu.edu.cn
China, Ningbo, 315211
Supplementary files
